President Donald Trump’s nominee to be the White House’s top drug policy adviser avoided providing her position on cannabis rescheduling and medical cannabis legalization when pressed by a pair of U.S. senators.Sara Carter, the president’s pick to be the director of the White House Office of National Drug Control Policy (ONDCP), merely said she would…...
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
